# Intarcia Therapeutics

Organization · id `cardio:org-intarcia-therapeutics` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Intarcia+Therapeutics>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 6 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Intarcia Therapeutics
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes (`cardio:ct-nct01455857`)
- Sponsors: A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes (`cardio:ct-nct01455870`)
- Sponsors: A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650 (`cardio:ct-nct01455896`)
- Sponsors: A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c (`cardio:ct-nct01785771`)
- Sponsors: Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide (`cardio:ct-nct02638805`)
- Sponsors: Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin (`cardio:ct-nct03060980`)

## Provenance

Content hash: 8eb0cce5300483fd42abc3ce4b020ec9c87b9af336403f3c312366b79ad5560b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
